Share-based Payment Arrangement, Expense of SpringWorks Therapeutics, Inc. from 30 Sep 2018 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
SpringWorks Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2018 to 31 Mar 2025.
  • SpringWorks Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $29,948,000, a 1.7% decline year-over-year.
  • SpringWorks Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2025 was $108,626,000, a 6.9% increase year-over-year.
  • SpringWorks Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $109,140,000, a 15% increase from 2023.
  • SpringWorks Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $94,534,000, a 30% increase from 2022.
  • SpringWorks Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $72,965,000, a 90% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

SpringWorks Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $108,626,000 $29,948,000 -$514,000 -1.7% 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 $109,140,000 $26,470,000 +$1,404,000 +5.6% 01 Oct 2024 31 Dec 2024 10-K 20 Feb 2025 2024 FY
Q3 2024 $107,736,000 $25,963,000 +$2,864,000 +12% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 $104,872,000 $26,245,000 +$3,271,000 +14% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2024 2024 Q2
Q1 2024 $101,601,000 $30,462,000 +$7,067,000 +30% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q4 2023 $94,534,000 $25,066,000 +$6,142,000 +32% 01 Oct 2023 31 Dec 2023 10-K 20 Feb 2025 2024 FY
Q3 2023 $88,392,000 $23,099,000 +$4,581,000 +25% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $83,811,000 $22,974,000 +$4,545,000 +25% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $79,266,000 $23,395,000 +$6,301,000 +37% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $72,965,000 $18,924,000 +$7,042,000 +59% 01 Oct 2022 31 Dec 2022 10-K 20 Feb 2025 2024 FY
Q3 2022 $65,923,000 $18,518,000 +$7,806,000 +73% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $58,117,000 $18,429,000 +$9,634,000 +110% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 $48,483,000 $17,094,000 +$10,039,000 +142% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q4 2021 $38,444,000 $11,882,000 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q3 2021 $10,712,000 +$7,669,000 +252% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $8,795,000 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $7,055,000 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q3 2020 $3,043,000 +$2,255,000 +286% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q3 2019 $788,000 +$553,000 +235% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2019 2019 Q3
Q3 2018 $235,000 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3

SpringWorks Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $109,140,000 +$14,606,000 +15% 01 Jan 2024 31 Dec 2024 10-K 20 Feb 2025 2024 FY
2023 $94,534,000 +$21,569,000 +30% 01 Jan 2023 31 Dec 2023 10-K 20 Feb 2025 2024 FY
2022 $72,965,000 +$34,521,000 +90% 01 Jan 2022 31 Dec 2022 10-K 20 Feb 2025 2024 FY
2021 $38,444,000 +$28,410,000 +283% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $10,034,000 +$6,925,000 +223% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $3,109,000 +$2,040,000 +191% 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
2018 $1,069,000 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.